Skip to Content
  • Article
  • Open Access

1 January 2006

Morbus Wilson: eine klinische und molekularbiologische Kasuistik †

,
,
,
and
1
Molekularbiologie/Genetik Viollier AG Spalenring 145/147 CH-4002 Basel
2
Medizinische Poliklinik, Universitätsspital Zürich
3
Facharzt FMH für Allgemeine Medizin, Tuggen
4
Neurologische Klinik, Universitätsspital Zürich

Abstract

Wilson’s disease is a rare autosomal recessively inherited disorder of copper metabolism resulting in accumulation of copper in many organs. The Kayser-Fleischer corneal ring represents a typical symptom in Wilson patients. ATP7B, the gene product of the Wilson’s disease gene, is expressed in hepatocytes and plays a critical role in copper transport and secretion. Mutations encompassing this gene leading to amino acid substitutions reduce the affinity of the ATPase enzyme to copper and prevent the transport of copper through the hepatocytes into the bile duct. More than 200 mutations in the 21 coding exons of the Wilson’s disease gene ATP7B have been described, the most common European one being His1069Gln (30–60% in European patients).Wilson’s disease may present with various clinical symptoms, commonly as liver and neuropsychiatric disease. The diagnosis of Wilson’s disease (prevalence 1:30 000) is based on a combination of clinical and neurological symptoms (Kayser-Fleischer corneal ring, MRI), a multi-parametric clinical chemistry panel (ceruloplasmin, 24 h-copper excretion in urine, serum copper) and molecular genetic analysis of ATP7B gene mutations. Symptomatic patients are treated with the chelating agents D-penicillamine or trientine, and in a second phase often with zinc. Lifelong therapy is required and provides life expectancy near to normal. Here, we report on the long-term follow-up of a 30-year-old Wilson patient displaying a compound heterozygosity of His1069Gln – Asn1270Ser mutations in the ATP7B gene as diagnosed by LightCycler real time polymerase chain reaction and DNA sequencing of exon 18. Molecular family-pedigree analysis over four generations revealed seven additional heterozygous mutation carriers. Treatment of the index patient with high doses of chelating agent D-penicillamine (1500 mg/d) in combination with zinc (150 mg/d) could reverse copper encephalopathy to normal and markedly reduced neurological symptoms. Kayser-Fleischer corneal ring was persistent. Wilson’s disease should be taken into consideration in case of any liver disease of unknown origin or neuropsychiatric symptoms. Current diagnostic panels (international scoring system) encompassing clinical chemistry and molecular genetics for screening and confirmation of Wilson’s disease are discussed.

Article Metrics

Citations

Article Access Statistics

Multiple requests from the same IP address are counted as one view.